Longeveron Executives to Speak at Global CardioVascular Clinical Trialists Forum.

Longeveron Inc. announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will speak at the Global CardioVascular Clinical Trialists Forum in Washington, D.C. Dr. Hare will participate in panel discussions on cell therapy for heart failure, including the importance of cell delivery route and the effectiveness of intravenous delivery. He will also discuss mesenchymal stem cell therapy for dilated cardiomyopathy, highlighting lessons learned from POSEIDON and PATH AHEAD trials.